Here's the Next Blockbuster Vaccine Opportunity for Pfizer
Comirnaty, the COVID-19 vaccine marketed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), should rake in $33.5 billion in sales this year. Pfizer also claims the world's second best-selling vaccine. The company won U.S. regulatory approval for a successor product, Prevnar 20, in immunizing adults earlier this summer.